Gastric acid suppression could improve heartburn by healing oesophagitis or by reduction of oesophageal sensitivity to acid. To independently assess changes in oesophageal sensitivity, it would be necessary to study patients with reflux disease but no oesophagitis. The aim ofthis study was to investigate the effect of acid suppression on oesophageal sensitivity and to assess the time course of any measured effect. Twenty seven patients were recruited, of whom 25 completed the study (14 men and 11 women, mean (SD) age 50 (15) (23), and 144 (25) seconds for weeks 4, 5, and 8). Heartburn symptom score decreased significantly with famotidine (mean scores 3*6, 1-9, 2*1, and 2-6 at weeks 0, 4, 5, and 8 (p=0 001)) and showed a significant negative correlation with time to heartburn (rs=-0*60; p<0)0001).
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It is concluded that oesophageal sensitivity to acid is reduced by famotidine independent of an effect on oesophagitis; the effect wanes one to four weeks after the end of treatment and correlates with change in heartburn score. (Gut 1994; 35: 447-450) Numerous treatment studies of patients with gastro-oesophageal reflux have shown that suppression of gastric acid has a beneficial effect on symptoms'; two early controlled studies with cimetidine showed in addition that active treatment resulted in an increase in the time to heartburn during oesophageal acid perfusion. 23 Because most studies have recruited patients with endoscopic oesophagitis, however, it is difficult to know whether symptomatic improvement is a result of improvement in the oesophagitis or some other factor. It Acid perfusion test'4 was carried out in a single blind fashion by inserting a naso-oesophageal tube with the distal margin 10 cm above the gastro-oesophageal mucosal junction whose position had been determined at endoscopy (5 cm added for nasal insertion). Perfusion was started with normal saline at a rate of 10 ml/min for 10 
Results
Two patients defaulted from further follow up after enrolment and could therefore not be evaluated further (both were taking placebo). This left 25 (14 famotidine, 11 placebo) who completed the study. Compliance (>95%, as assessed by tablet counts) among these 25 was excellent. The mean % total time oesophageal pH <4 during 24 hour pH monitoring was 10.7 (0.8)% (range 5-9-19) for the 25 patients who completed the study. Median (range) of symptom indices was 100 (50-100)%. Thus, all had objective evidence of gastro-oesophageal reflux induced heartburn.
Mean time to heartburn during acid perfusion (oesophageal mucosal sensitivity) was not significantly different between the active and placebo groups at any time during the study, though there was a trend at weeks 4 and 5 for a longer time in the active group (week 0: 124 (21) v 187 (46), p=0.2; week 4: 452 (102) v 218 (41), p=0 07; week 5: 346 (92) v 146 (23), p=007; week 8: 276 (90) v 144 (25), p=0-2 for active and placebo groups respectively). Within groups, however, there was a significant decrease in oesophageal mucosal sensitivity at weeks 4 and 5 compared with baseline in the active but not the placebo group (Fig 1) . The lack of intergroup difference is explained by examining the data for individual patients (Figs 2 and 3) , from which it is evident that most patients (except one) in the placebo group showed little change in time to heartburn over the eight weeks of the study, whereas among the active group, there were two apparent subsets: eight patients increased the 14) .
time to heartburn while six did not. Heartburn grading improved in the active compared with the placebo group at weeks 4 (p<0 01) and 5 (p<0 05), but was not different at baseline or week 8 (Fig 4) . Within groups, heartburn grades improved at weeks 4, 5, and 8 compared with baseline for active (p<0 005) but not placebo group (NS; Fig 4) . When patients receiving active treatment were subdivided into non-responders (increase in time to heartburn at week 4 over baseline 100 seconds or less; n=6) or responders (increase in time to heartburn >150 seconds; n=8), there was a significant difference mean (SEM) in heartburn grade at week 4 (nonresponders 2-7 (0.5) v responders 1V4 (0.2); p<0O02). Furthermore, patients in the active A°group could be subdivided into those in whom decreased oesophageal mucosal sensitivity was -> maintained (n=4) and those in whom it was not (n= 10; see Fig 2) . The heartburn grade at week 8 was lower in the first compared with the second (1 3 (0.3) v 3d1 (0.2); p<0001). There was a significant correlation between grade of heartburn and time to heartburn during acid perfusion (rs=-0 6, p<00001; Fig 5) This finding also suggests that antacids, which were available to both groups of patients ad libitum had little discernible effect, because it might be expected that the maximum effect would occur in patients taking placebo. The close relation between heartburn score and time to heartburn during oesophageal acid perfusion supports the hypothesis that improved symptoms of heartburn are related to decreased oesophageal mucosal sensitivity. This conclusion is supported by the findings of better heartburn improvement in the subgroups of patients receiving active treatment in whom mucosal sensitivity was decreased and in whom this decrease was maintained to the end of the study. It would be interesting in further studies to investigate if more profound acid suppression (for example, with proton pump inhibitors) both increased the proportion of patients with decreased oesophageal mucosal sensitivity and increased the proportion in whom this improvement was maintained. Although the mechanisms underlying changes in oesophageal mucosal sensitivity to acid are not well understood, increasing the proportion of patients who maintain a decreased acid sensitivity will increase the symptom remission rate and duration.
In conclusion, famotidine at a dose of 40 mg twice daily reduces symptoms of heartburn and decreases oesophageal mucosal sensitivity in patients with symptomatic gastro-oesophageal reflux disease but no oesophagitis, and suggests that, at least in this group ofpatients, the two are closely related.
